Risk adjusted net present value: What is the current valuation of AstraZeneca’s Saruparib?

Saruparib is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Metastatic Prostate Cancer.

Our Top 10 Psychedelics Articles in 2023 – Psychedelic Alpha

Our Top 10 Psychedelics Articles in 2023January 11, 2024 To kick off our 2023 Year in Review, Josh looks back at some of our top

January 11, 2024

Study reveals vascular health disparities between Black and white men with prostate cancer diagnosis

Microvascular function is lower is Black men following a recent diagnosis of prostate cancer, compared to white men, according to researchers at the Medical College

April 7, 2024

Abbott’s dissolvable stent, which failed in heart disease patients, may help vascular patients

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease. The device is a below-knee

May 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.